Even though insulin sensitivity might not be affected by SGLT2i [21], the potential reduction of visceral adipose tissue and also hepatic gluconeogenesis [22], SGLT2i may directly and indirectly mitigate vital effects of MASLD progression. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.